ADC Therapeutics SA
NYSE:ADCT
Gross Margin
ADC Therapeutics SA
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
Country | Company | Market Cap |
Gross Margin |
||
---|---|---|---|---|---|
CH |
ADC Therapeutics SA
NYSE:ADCT
|
176.9m USD |
94%
|
||
FR |
Pharnext SCA
OTC:PNEXF
|
6T USD |
0%
|
||
US |
Abbvie Inc
NYSE:ABBV
|
303.2B USD |
67%
|
||
US |
Amgen Inc
NASDAQ:AMGN
|
146.3B USD |
60%
|
||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
114.4B USD |
78%
|
||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.8B USD |
86%
|
||
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
76%
|
|
AU |
CSL Ltd
ASX:CSL
|
132.7B AUD |
52%
|
||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
75B USD |
87%
|
||
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
75%
|
|
NL |
argenx SE
XBRU:ARGX
|
38.1B EUR |
89%
|
ADC Therapeutics SA
Glance View
ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on ADC Therapeutics SA's most recent financial statements, the company has Gross Margin of 94.2%.